Clinical Trials Browser

Phase 1 × Interventional × dalotuzumab × Clear all

NCT00635778 2018-10-09

MK-0646-002

Phase 1 Completed

50 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT00759785 2018-08-15

MK-0646-013

Phase 1 Completed

48 enrolled 10 charts

Breast Neoplasms

NCT00925015 2018-08-15

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Phase 1 Completed

20 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT00694356 2018-08-08

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Phase 1 Completed

15 enrolled 13 charts

Neoplasms

NCT00701103 2018-08-08

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Phase 1 Completed

80 enrolled 23 charts

Multiple Myeloma

NCT01431547 2016-06-17

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT00729742 2016-04-04

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00730379 2015-02-10

A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Phase 1 Completed

Neoplasms

NCT01220570 2015-01-21

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Phase 1 Completed

Breast Neoplasms